-
Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia
•
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership with Mirxes Singapore. Together, they will utilize their combined technological and operational strengths to offer solid tumor origin identification testing services to medical practitioners and patients in Singapore, Malaysia, Thailand, Indonesia, and the Philippines. Collaboration…
-
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
•
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit products, has submitted an updated initial public offering (IPO) prospectus to the Hong Kong Stock Exchange. The document reveals the company’s financial performance as of June 2024. During the first half of the year, Mirxes…
-
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
•
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the Hong Kong Stock Exchange (HKEX) in anticipation of a public listing. The firm is targeting a minimum capital raise of USD 100 million, aiming for a valuation of at least USD 600 million. This follows…
